OOIR: Observatory of International Research

Papers

(The TQCC of Annals of the Rheumatic Diseases is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry	846
Global, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the Global Burden of Disease Study 2017	597
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update	541
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study	463
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry	453
Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort	371
Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies	366
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update	334
Update οn the diagnosis and management of systemic lupus erythematosus	308
Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort	258
Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis	228
EULAR definition of difficult-to-treat rheumatoid arthritis	217
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update	213
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity	201
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study	194
Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression	184
Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study	175
Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series	173
Microenvironment in subchondral bone: predominant regulator for the treatment of osteoarthritis	171
Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US ‘hot spot’	168
Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine	166
Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease	164
EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2	163
Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database	156
2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis	155

Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases	153
Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2	153
Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study	152
Preliminary predictive criteria for COVID-19 cytokine storm	150
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial	149
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors	147
SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases	146
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement	145
2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis	141
Paradoxical gastrointestinal effects of interleukin-17 blockers	134
Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases	132
Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19	131
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data	131
EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome	129
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2	128
JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib	123
Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients	122
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry	122
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial	121
Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry	121
METTL3-mediated m⁶A modification of ATG7 regulates autophagy-GATA4 axis to promote cellular senescence and osteoarthritis progression	121
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study	120
Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme	120
2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis	118
Axial spondyloarthritis	118
Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)	116
Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome	116
2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis	109
Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging	109
SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response	108
Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases	107
EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis	101
Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China	100
Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial	100
Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases	98
Anti-inflammatory therapy for COVID-19 infection: the case for colchicine	98
Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial	98
Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era	97
Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia	96
EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update	96
2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis	96
Incidence trend of five common musculoskeletal disorders from 1990 to 2017 at the global, regional and national level: results from the global burden of disease study 2017	94
High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases	94
Large-scale meta-analysis across East Asian and European populations updated genetic architecture and variant-driven biology of rheumatoid arthritis, identifying 11 novel susceptibility loci	93
Meta-analysis of 208370 East Asians identifies 113 susceptibility loci for systemic lupus erythematosus	92
COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD	91
Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab	91
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis	89
Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis	89
Myositis as a manifestation of SARS-CoV-2	88

Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study	87
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controll	87
Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis	84
EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update	82
Unique expansion of IL-21+ Tfh and Tph cells under control of ICOS identifies Sjögren’s syndrome with ectopic germinal centres and MALT lymphoma	80
Pathogenic UBA1 variants associated with VEXAS syndrome in Japanese patients with relapsing polychondritis	80
Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials	79
Transcutaneous auricular vagus nerve stimulation reduces pain and fatigue in patients with systemic lupus erythematosus: a randomised, double-blind, sham-controlled pilot trial	79
Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong	78
Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study	78
COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine	77
Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis	75
Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to m	75
Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations	74
Response to: ‘Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry’’	73
What is the true incidence of COVID-19 in patients with rheumatic diseases?	72
Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis	72
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database	71
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial	71
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial	70
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular	69
Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study	68
2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases	68
Gout and pseudo-gout-related crystals promote GLUT1-mediated glycolysis that governs NLRP3 and interleukin-1β activation on macrophages	67
A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis	67
Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden	67
Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases	66
Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City	64
Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic	64
Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases	63
Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases	62
Salivary gland epithelial cells from patients with Sjögren’s syndrome induce B-lymphocyte survival and activation	61
Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial	61
Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies	60
Infections in baricitinib clinical trials for patients with active rheumatoid arthritis	59
Efficacy and safety of abatacept in active primary Sjögren’s syndrome: results of a phase III, randomised, placebo-controlled trial	59
Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts	58
Mechanical overloading promotes chondrocyte senescence and osteoarthritis development through downregulating FBXW7	58
SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists	57
circPDE4B prevents articular cartilage degeneration and promotes repair by acting as a scaffold for RIC8A and MID1	57
2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis	57
Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial	56
Antibodies against immunogenic epitopes with high sequence identity to SARS-CoV-2 in patients with autoimmune dermatomyositis	56
Postvaccination antibody titres predict protection against COVID-19 in patients with autoimmune diseases: survival analysis in a prospective cohort	56
Does cartilage loss cause pain in osteoarthritis and if so, how much?	55
The microbiome in rheumatology: Where are we and where should we go?	55
Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept	55
Machine-learning, MRI bone shape and important clinical outcomes in osteoarthritis: data from the Osteoarthritis Initiative	55
Normal human enthesis harbours conventional CD4+ and CD8+ T cells with regulatory features and inducible IL-17A and TNF expression	55
Canakinumab for Treatment of Adult-Onset Still’s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-i	54
Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis	54
Dysbiosis in the oral microbiomes of anti-CCP positive individuals at risk of developing rheumatoid arthritis	53
Associations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study	53
Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis	52
2022 EULAR points to consider for remote care in rheumatic and musculoskeletal diseases	52
Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis	52
BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus	52
Case of acute arthritis following SARS-CoV-2 infection	51
‘SMASH’ recommendations for standardised microscopic arthritis scoring of histological sections from inflammatory arthritis animal models	51
Osteoarthritis endotype discovery via clustering of biochemical marker data	51
High prevalence of spondyloarthritis-like MRI lesions in postpartum women: a prospective analysis in relation to maternal, child and birth characteristics	51
Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial	51
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial	51
Presence of antiphospholipid antibodies in COVID-19: a case series study	51
Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab	50
Tocilizumab in VEXAS relapsing polychondritis: a single-center pilot study in Japan	50
Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19	50
Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort	50
Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus	50
A pilot study of tofacitinib for refractory Behçet’s syndrome	50
Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying	50
Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: a population-based cohort study	50
Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management	49
Efficacy of tocilizumab in patients with hand osteoarthritis: double blind, randomised, placebo-controlled, multicentre trial	48
Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis	48
Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration	48
Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial	48
COVID-19 and rheumatology: first steps towards a different future?	48
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial	48
Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence	48

Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases	47
Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis	47
Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries	47
Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction	47
Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles	47
Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study	47
Temporary hold of mycophenolate augments humoral response to SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases: a case series	46
Case series of acute arthritis during COVID-19 admission	46
Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis	46
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised,	46
Transient monoarthritis and psoriatic skin lesions following COVID-19	46
Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis	46
SAT0409 BIOLOGIC TREATMENT IN PSORIATIC ARTHRITIS AND AXIAL SPONDYLOPATHY REDUCES SICKNOTES ISSUED BY GPS, DESPITE DELAYS IN DIAGNOSIS: A REAL-LIFE STUDY IN WALES.	46
TRIM24-RIP3 axis perturbation accelerates osteoarthritis pathogenesis	45
Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey	45
Onset of rheumatoid arthritis after COVID-19: coincidence or connected?	45
Clinical characteristics and treatment of 50 cases of Blau syndrome in Japan confirmed by genetic analysis of the NOD2 mutation	45
Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study	45
EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs	44
Response to: ‘‘2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus’ by Aringeret al’ by Cuiet al	44
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis	43
Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis	43
In vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells	43
Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance	43
Combination of human umbilical cord mesenchymal stem (stromal) cell transplantation with IFN-γ treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis	43
Identification of the skeletal progenitor cells forming osteophytes in osteoarthritis	43
Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets	42
EULAR recommendations for intra-articular therapies	42
2023 ACR/EULAR antiphospholipid syndrome classification criteria	42
Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study	41
Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort	41
Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial	41
Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial	41
AB0606 IMPACT OF ABDOMINAL AORTIC CALCIFICATION AND SERUM CREATININE-TO-CYSTATIN C RATIO TO BONE FRAGILITY FRACTURE	41
Serum NT/CT SIRT1 ratio reflects early osteoarthritis and chondrosenescence	41
Proteomic, biomechanical and functional analyses define neutrophil heterogeneity in systemic lupus erythematosus	41
Systemic evaluation of the relationship between psoriasis, psoriatic arthritis and osteoporosis: observational and Mendelian randomisation study	40
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update	40
Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years	40
Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case–control study	40
Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial	40
FRI0506 EFFICACY AND SAFETY OF CANAKINUMAB IN ADULT-ONSET STILL’S DISEASE: A SINGLE-CENTER REAL-LIFE EXPERIENCE	40
Quantitative planar array screen of 1000 proteins uncovers novel urinary protein biomarkers of lupus nephritis	40
Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial	39
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial	39
TGFβ attenuates cartilage extracellular matrix degradation via enhancing FBXO6-mediated MMP14 ubiquitination	38
Blood-brain barrier leakage in systemic lupus erythematosus is associated with gray matter loss and cognitive impairment	38
Metagenome-wide association study revealed disease-specific landscape of the gut microbiome of systemic lupus erythematosus in Japanese	38
Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis	38
Efficacy of COVID-19 vaccines in patients taking immunosuppressants	38
The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndr	38
COVID-19 in patients with rheumatological diseases treated with anti-TNF	38
To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic	38
Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behçet’s phenotype: a multicentre study	37
Precise targeting of miR-141/200c cluster in chondrocytes attenuates osteoarthritis development	37
Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series	37
Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial	37
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials	37
Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trial	37
Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis	37
Whole gut virome analysis of 476 Japanese revealed a link between phage and autoimmune disease	37
Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients	37
Regulatory eosinophils induce the resolution of experimental arthritis and appear in remission state of human rheumatoid arthritis	37
Role of immunosuppressive therapy in rheumatic diseases concurrent with COVID-19	36
Choose wisely: imaging for diagnosis of axial spondyloarthritis	36
Are patients with systemic lupus erythematosus at increased risk for COVID-19?	36
Safety and disease flare of autoimmune inflammatory rheumatic diseases: a large real-world survey on inactivated COVID-19 vaccines	36
Severe COVID-19 and related hyperferritinaemia: more than an innocent bystander?	36
Treat-to-target study for improved outcome in polyarticular juvenile idiopathic arthritis	36
EULAR recommendations for a core data set for pregnancy registries in rheumatology	36
Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases	36
Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α	36
Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence–radiological differences	36
BCP crystals promote chondrocyte hypertrophic differentiation in OA cartilage by sequestering Wnt3a	35
Age-associated B cells contribute to the pathogenesis of rheumatoid arthritis by inducing activation of fibroblast-like synoviocytes via TNF-α-mediated ERK1/2 and JAK-STAT1 pathways	35
Burden and trajectory of multimorbidity in rheumatoid arthritis: a matched cohort study from 2006 to 2015	35
COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs	35
Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort	35
Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study	35
Comparative analysis of synovial inflammation after SARS-CoV-2 infection	34
European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance	34
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance	34
EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update	34
Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID)	34
2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases	34
Horizontal fissuring at the osteochondral interface: a novel and unique pathological feature in patients with obesity-related osteoarthritis	34
Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis	34
Activation of acid-sensing ion channel 3 by lysophosphatidylcholine 16:0 mediates psychological stress-induced fibromyalgia-like pain	34
Mechanosensitive TRPV4 is required for crystal-induced inflammation	34
Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases	33
Festina lente: hydroxychloroquine, COVID-19 and the role of the rheumatologist	33
Time to reconsider what Global Burden of Disease studies really tell us about low back pain	33
Synovial fibroblasts assume distinct functional identities and secrete R-spondin 2 in osteoarthritis	33
Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing	33
Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study	33